C4 Therapeutics
CCCC
148 hedge funds and large institutions have $548M invested in C4 Therapeutics in 2026 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 54 increasing their positions, 27 reducing their positions, and 27 closing their positions.
582% more call options, than puts
Call options by funds: $4.58M | Put options by funds: $672K
147% more capital invested
Capital invested by funds: $221M → $548M (+$326M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 27
93% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 27
20% more funds holding
Funds holding: 123 → 148 (+25)
19.79% more ownership
Funds ownership: 86.59% → 106.38% (+20%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$20M |
| 2 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
+$16.9M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$8.32M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$6.15M |
| 5 |
State Street
Boston,
Massachusetts
|
+$5.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$4.35M |
| 2 |
Millennium Management
New York
|
-$4.03M |
| 3 |
Jane Street
New York
|
-$3.23M |
| 4 |
O
OrbiMed
New York
|
-$2.25M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.46M |
CCCC Hedge Fund Activity: Q2 2026 in Review
148 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q2 2026, worth a combined $548M — up 147% from $221M a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new CCCC positions and 27 closed out — a net gain of 25 holders — while 54 added to existing stakes and 27 trimmed.
The largest buyer was BlackRock, adding an estimated $20M. The largest seller was Renaissance Technologies, cutting an estimated $4.35M.
- 148 institutional investors held C4 Therapeutics (CCCC) as of Q2 2026, up from 123 in Q1 2026.
- Funds reported $548M of C4 Therapeutics stock for Q2 2026, up 147% quarter-over-quarter.
- 52 funds opened new C4 Therapeutics positions in Q2 2026 and 27 closed out, a net change of +25 holders.
- The largest C4 Therapeutics buyer in Q2 2026 was BlackRock, an estimated $20M added.
- The largest C4 Therapeutics seller in Q2 2026 was Renaissance Technologies, an estimated $4.35M sold.
Based on aggregated 13F filings for Q2 2026.